Bio-Rad Laboratories Inc (NYSE:BIO). reported its fourth-quarter 2024 earnings, revealing a slight miss on revenue expectations, with net sales of $668 million compared to a forecast of $681.29 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback